Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Jul;70(1):151-3.
doi: 10.1038/bjc.1994.266.

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb

Affiliations
Free PMC article

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb

J M Klaase et al. Br J Cancer. 1994 Jul.
Free PMC article

Abstract

In 14 consecutive patients with recurrent melanoma of the lower limb a total of 35 biopsies were taken at the end of perfusion treatment to assess melphalan tissue concentrations in tumour, skin/subcutis and muscle tissue. In tumour tissue (n = 12) the mean melphalan concentration was 6.8 micrograms g-1, which was significantly higher than that of healthy skin/subcutis (3.2 micrograms g-1; n = 10), but equal to that of muscle tissue (6.5 micrograms g-1; n = 13). The correlation between melphalan concentration in the tissues and the concentration in the perfusate was studied. The latter was assessed in the form of melphalan peak concentration and the area under the curve (AUC0-->60) of the melphalan concentration-time curve. Tumour concentration proved to be correlated linearly with AUC0-->60 (R = 0.6, P = 0.002) and muscle concentration with melphalan peak concentration (R = 0.8, P = 0.04). There was no relation between skin/subcutis concentrations and the perfusate parameters. Further research is warranted to study the relationship between melphalan tissue concentration, tumour response and regional toxicity.

PubMed Disclaimer

References

    1. J Pharm Sci. 1978 May;67(5):682-4 - PubMed
    1. Cancer Lett. 1980 Sep;10(3):243-51 - PubMed
    1. Cancer Res. 1981 Apr;41(4):1525-34 - PubMed
    1. Science. 1956 Jun 1;123(3205):984-5 - PubMed
    1. Eur J Surg Oncol. 1988 Apr;14(2):101-10 - PubMed